實地考察健康報告第四季度淨虧損0.25美元，未達到預期；提供公司重組更新

07:22 AM EDT, 06/30/2022 (MT Newswires) -- Field Trip Health (FTRP.TO), in psychedelic therapies, overnight Wednesday reported its Q4 2022 results and corporate reorganization update.

The company generated revenue of $1.72 million, missing a Capital IQ forecast of $1.91 million but more than three times higher than Q4 2021's revenue of $526,000.

Net loss was $14.1 million, or $(0.25) per diluted share, missing the Capital IQ forecast of $(0.23). The increased net loss was due to higher operating losses. Field Trip reported a net loss of $7.95 million, or $(0.18) per share, for the prior year quarter.

As of March 31, 2022, Field Trip had unrestricted cash and cash equivalents and restricted cash of $64.5 million.

Post quarter end, Field Trip announced plans to separate the Field Trip Discovery and Field Trip Health Divisions into two public companies via a plan of arrangement. Field Trip Discovery, to be renamed Reunion Neuroscience, wll focus on the research and development of novel psychedelic molecules like FT-104. Field Trip Health will be renamed Field Trip Health & Wellness (Field Trip H&W) and will develop competitive and differentiated psychedelic-assisted therapies (PAT) to achieve the best patient outcomes in the treatment of mental health and mood disorders.

Each share of the company will be exchanged for one common share of Reunion and 0.86 common shares of Field Trip H&W. Reunion will remain listed on the Nasdaq and TSX, and Field Trip H&W, subject to exchange approval, will list on the TSXV.

Field Trip H&W is expected to complete private placement financings for gross proceeds of $20 million. Field Trip said on June 14 that it would up its initial investment from $5 million to $9.8 million for a 21.79% equity interest in Field Trip H&W.

On June 27, the company announced its shareholders had approved the spinout transaction. Field Trip also received final court approval for the transaction on June 29 and the Arrangement is expected to close in August.